Myelodest

2023: Start of Production

Pharmasintez-Nord has released at its enterprise, which is located in the special economic zone (SEZ) "St. Petersburg," the first batch of the drug with the active substance for the therapy of multiple myeloma. This was reported in the group in early October 2023.

The medicine contains pomalidomide, which will help patients over 18 years of age during treatment for a malignant plasma cell tumor. The drug was registered in June 2023 and is available in three doses - 1 mg, 2 mg and 4 mg.

Multiple myeloma is a malignant plasma cell tumor that produces monoclonal immunoglobulins that invade and destroy adjacent bone tissue. Manifestations of the disease include lytic bone lesions, fractures, renal failure, hypercalcemia, anemia and recurrent infections.

Pomalidomide is used in combination with other drugs used in the complex therapy of cancer.

Multiple myeloma usually does not respond to treatment, told the company "Farmasintez-Nord." However, signs and symptoms can be significantly reduced due to a properly selected treatment regimen. Pomalidomide is able to act on the body's immune system and directly on cancer cells.

As noted by Mikhail Kvasnikov, General Director of Farmasintez-Nord JSC, by the beginning of October 2023, the company's production of anticancer drugs is 5.6 million packages per year.

The total investment in four phases is estimated at about 20 billion rubles. Of these, 9 billion rubles have already been spent by the beginning of October 2023. By this time, the company had commissioned two stages of the production complex. The launch of the third stage is scheduled for 2026.^[1]

Notes